This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Checkpoint Therapeutics Stock (NASDAQ:CKPT) Get CKPT alerts:Sign Up Key Stats Today's Range$4.26▼$4.2650-Day Range$4.15▼$4.2952-Week Range$4.04▼$4.28VolumeN/AAverage Volume1.92 million shsMarket Capitalization$370.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Read More Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CKPT Stock News HeadlinesTrunk and disorderly: Two Malaysians’ alleged 3am boot escape foiled at Woodlands CheckpointJuly 9, 2025 | msn.comTrunk and disorderly: Two Malaysians’ alleged boot escape bid foiled at Woodlands CheckpointJuly 8, 2025 | msn.comYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - at no charge. Inside, he reveals the one options technique that took him 11 years to find, why more strategies often lead to more losses, and the 10-minute nightly routine that replaced his 8-hour trading days.May 20 at 1:00 AM | Profits Run (Ad)Checkpoint Therapeutics finalizes acquisition by Sun PharmaJune 1, 2025 | uk.investing.comSun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT)May 30, 2025 | insidermonkey.comCheckpoint Therapeutics shareholders approve Sun Pharma mergerMay 30, 2025 | investing.comCheckpoint Therapeutics Completes Merger with Sun Pharma SubsidiaryMay 30, 2025 | tipranks.comCheckpoint Therapeutics Announces Merger ProgressMay 24, 2025 | uk.investing.comSee More Headlines CKPT Stock Analysis - Frequently Asked Questions How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its earnings results on Tuesday, May, 13th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.09. When did Checkpoint Therapeutics' stock split? Shares of Checkpoint Therapeutics reverse split on Sunday, December 4th 2022.The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include TG Therapeutics (TGTX), Bionano Genomics (BNGO), Fortress Biotech (FBIO), NIO (NIO), uniQure (QURE), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/13/2025Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CKPT's financial health is in the Green zone, according to TradeSmith. CKPT has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CKPT CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.85 million Net MarginsN/A Pretax Margin-98,868.08% Return on EquityN/A Return on Assets-659.07% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual Sales$41 thousand Price / Sales9,041.59 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-9.06Miscellaneous Outstanding Shares87,020,000Free Float47,808,000Market Cap$370.71 million OptionableOptionable Beta1.18 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CKPT) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredThis Biotech Just Flipped From Story to ExecutionAvai Bio (OTCQB: AVAI) has moved into production on its new Master Cell Bank, developed alongside Austrianova,...Equiscreen | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
